13F Pro

SEC Form 4 reporting owner

Bedrosian Camille L

Bedrosian Camille L has filed 16 Form 4 transactions reported between December 1, 2025 and September 10, 2026, as Chief Medical Officer of Amylyx Pharmaceuticals, Inc. and Director of Crinetics Pharmaceuticals, Inc..

Name as filed: Bedrosian Camille L

Open-market buys, 24 mo
None
reported
Open-market sales, 24 mo
$513K
4 lines
Companies
2
with Form 4 filings
Latest transaction
Sep 10, 2026
transaction date

Roles and reported holdings

  • AMLXAmylyx Pharmaceuticals, Inc.
    Dec 1, 2025 – Sep 10, 2026

    Chief Medical Officer

    Held directly278,064 sh as of Sep 10, 2026 · Form 4

    24 months: $513K sold

  • CRNXCrinetics Pharmaceuticals, Inc.
    Jun 18, 2026 – Sep 1, 2026

    Director

    No common-stock holding reported on a purchase, sale, gift or withholding line.

Transaction history

All 16 reported transactions, newest first. Every row links to the Form 4 on SEC EDGAR.

DateCompanyTypeSharesValueFiling
Sep 10, 2026AMLXChief Medical OfficerOpen-market saleCode S · direct2,081$69K@ $33.09Form 4
Sep 10, 2026AMLXChief Medical OfficerOpen-market saleCode S · direct7,947$256K@ $32.21Form 4
Sep 1, 2026CRNXDirectorDisposition to issuerCode D · direct9,730$478K@ $49.13Form 4
Sep 1, 2026CRNXDirectorDisposition to issuerCode D · direct10,350$545K@ $52.67Form 4
Sep 1, 2026CRNXDirectorDisposition to issuerCode D · direct12,500$504K@ $40.29Form 4
Sep 1, 2026CRNXDirectorDisposition to issuerCode D · direct17,500$1.1M@ $64.77Form 4
Sep 1, 2026CRNXDirectorDisposition to issuerCode D · direct25,000$1.7M@ $68.92Form 4
Sep 1, 2026CRNXDirectorDisposition to issuerCode D · direct5,925$504K@ $85.00Form 4
Sep 1, 2026CRNXDirectorDisposition to issuerCode D · direct16,300$1.4M@ $85.00Form 4
Aug 18, 2026AMLXChief Medical OfficerGrant or awardCode A · direct22,807—Form 4
Jun 18, 2026CRNXDirectorGrant or awardCode A · direct9,730—Form 4
Jun 18, 2026CRNXDirectorGrant or awardCode A · direct5,925—Form 4
Mar 5, 2026AMLXChief Medical OfficerGrant or awardCode A · direct143,985—Form 4
Mar 5, 2026AMLXChief Medical OfficerGrant or awardCode A · direct95,990—Form 4
Mar 2, 2026AMLXChief Medical OfficerOpen-market saleCode S · direct6,461$94K@ $14.58Form 4
Dec 1, 2025AMLXChief Medical OfficerOpen-market saleCode S · direct6,580$94K@ $14.35Form 4

How this page is built

Every row comes from a Form 4 filed with the SEC, which officers, directors and holders of more than 10% of a company’s stock must file within two business days of a trade. Transactions are grouped by the reporting owner’s name as filed (spacing, capitals and punctuation ignored); two different people filing under an identical name would appear together, and one person filing under two spellings appears on two pages.

Open-market totals count code P purchases and code S sales over the last 24 months. The same trade reported on more than one filing is counted once; when another owner (for example a fund and its general partner) reports the identical trade, they are listed beside it. Holdings are the shares owned after the latest purchase, sale, gift or tax-withholding line, shown separately for direct and indirect ownership; an indirect figure is one holding line, not a total across every trust or entity.

This page describes what was filed with the SEC; it is not investment advice or a recommendation to buy or sell any security.